Video

Dr. Stratton discusses combo of avelumab and BCG in NMIBC

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Kelly L. Stratton, MD, discusses further research on the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” presented at the 2021 American Urological Association Annual Meeting, and his take on the current state of BCG-unresponsive non–muscle-invasive bladder cancer. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.